Interferon-α as angiogenesis inhibitor: Learning from tumor models

Research output: Contribution to journalArticle

Abstract

Interferon-α (IFN-α), a cytokine with marked therapeutic activity in transplantable tumor models, has been identified as powerful angiogenesis inhibitor. The effects of IFN-α on the vasculature have been mainly attributed to inhibition of basic fibroblast growth factor production by tumor cells or downregulation of IL-8 and vascular endothelial growth factor gene expression. Moreover, IFN-α has direct effects on endothelial cells (EC), including impairment of their proliferation and migration. The gene expression profile induced by IFN-α in EC has recently been defined, and it was found that several genes encoding negative regulators of angiogenesis are upmodulated, thus providing a potential amplification mechanism for this biological activity. The anti-angiogenic effects of IFN-α appear to be associated with increased hypoxia and ischemic necrosis in subcutaneous xenograft models, whereas in transgenic mouse models, IFN-α may simultaneously interfere with both blood vessels and tumor cell proliferation, leading to regression of tumors without necrosis. The consequences of IFN-α therapy on the invasive and metastatic behavior of tumor cells are currently unknown. Finally, as effective anti-angiogenic therapy with IFN-α demands sustained localized production of this cytokine, innovative strategies of targeted delivery of the IFN-α gene into tumors are discussed.

Original languageEnglish
Pages (from-to)244-247
Number of pages4
JournalAutoimmunity
Volume43
Issue number3
DOIs
Publication statusPublished - May 2010

Fingerprint

Angiogenesis Inhibitors
Interferons
Learning
Neoplasms
Necrosis
Endothelial Cells
Vascular Tissue Neoplasms
Cytokines
Fibroblast Growth Factor 2
Interleukin-8
Transcriptome
Heterografts
Vascular Endothelial Growth Factor A
Transgenic Mice
Genes
Therapeutics
Down-Regulation
Cell Proliferation
Gene Expression

Keywords

  • Angiogenesis
  • Cancer
  • Gene therapy
  • Hypoxia
  • Interferon

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Interferon-α as angiogenesis inhibitor : Learning from tumor models. / Indraccolo, Stefano.

In: Autoimmunity, Vol. 43, No. 3, 05.2010, p. 244-247.

Research output: Contribution to journalArticle

@article{8eb6ac63bfd246d9b199f9796d12750e,
title = "Interferon-α as angiogenesis inhibitor: Learning from tumor models",
abstract = "Interferon-α (IFN-α), a cytokine with marked therapeutic activity in transplantable tumor models, has been identified as powerful angiogenesis inhibitor. The effects of IFN-α on the vasculature have been mainly attributed to inhibition of basic fibroblast growth factor production by tumor cells or downregulation of IL-8 and vascular endothelial growth factor gene expression. Moreover, IFN-α has direct effects on endothelial cells (EC), including impairment of their proliferation and migration. The gene expression profile induced by IFN-α in EC has recently been defined, and it was found that several genes encoding negative regulators of angiogenesis are upmodulated, thus providing a potential amplification mechanism for this biological activity. The anti-angiogenic effects of IFN-α appear to be associated with increased hypoxia and ischemic necrosis in subcutaneous xenograft models, whereas in transgenic mouse models, IFN-α may simultaneously interfere with both blood vessels and tumor cell proliferation, leading to regression of tumors without necrosis. The consequences of IFN-α therapy on the invasive and metastatic behavior of tumor cells are currently unknown. Finally, as effective anti-angiogenic therapy with IFN-α demands sustained localized production of this cytokine, innovative strategies of targeted delivery of the IFN-α gene into tumors are discussed.",
keywords = "Angiogenesis, Cancer, Gene therapy, Hypoxia, Interferon",
author = "Stefano Indraccolo",
year = "2010",
month = "5",
doi = "10.3109/08916930903510963",
language = "English",
volume = "43",
pages = "244--247",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Interferon-α as angiogenesis inhibitor

T2 - Learning from tumor models

AU - Indraccolo, Stefano

PY - 2010/5

Y1 - 2010/5

N2 - Interferon-α (IFN-α), a cytokine with marked therapeutic activity in transplantable tumor models, has been identified as powerful angiogenesis inhibitor. The effects of IFN-α on the vasculature have been mainly attributed to inhibition of basic fibroblast growth factor production by tumor cells or downregulation of IL-8 and vascular endothelial growth factor gene expression. Moreover, IFN-α has direct effects on endothelial cells (EC), including impairment of their proliferation and migration. The gene expression profile induced by IFN-α in EC has recently been defined, and it was found that several genes encoding negative regulators of angiogenesis are upmodulated, thus providing a potential amplification mechanism for this biological activity. The anti-angiogenic effects of IFN-α appear to be associated with increased hypoxia and ischemic necrosis in subcutaneous xenograft models, whereas in transgenic mouse models, IFN-α may simultaneously interfere with both blood vessels and tumor cell proliferation, leading to regression of tumors without necrosis. The consequences of IFN-α therapy on the invasive and metastatic behavior of tumor cells are currently unknown. Finally, as effective anti-angiogenic therapy with IFN-α demands sustained localized production of this cytokine, innovative strategies of targeted delivery of the IFN-α gene into tumors are discussed.

AB - Interferon-α (IFN-α), a cytokine with marked therapeutic activity in transplantable tumor models, has been identified as powerful angiogenesis inhibitor. The effects of IFN-α on the vasculature have been mainly attributed to inhibition of basic fibroblast growth factor production by tumor cells or downregulation of IL-8 and vascular endothelial growth factor gene expression. Moreover, IFN-α has direct effects on endothelial cells (EC), including impairment of their proliferation and migration. The gene expression profile induced by IFN-α in EC has recently been defined, and it was found that several genes encoding negative regulators of angiogenesis are upmodulated, thus providing a potential amplification mechanism for this biological activity. The anti-angiogenic effects of IFN-α appear to be associated with increased hypoxia and ischemic necrosis in subcutaneous xenograft models, whereas in transgenic mouse models, IFN-α may simultaneously interfere with both blood vessels and tumor cell proliferation, leading to regression of tumors without necrosis. The consequences of IFN-α therapy on the invasive and metastatic behavior of tumor cells are currently unknown. Finally, as effective anti-angiogenic therapy with IFN-α demands sustained localized production of this cytokine, innovative strategies of targeted delivery of the IFN-α gene into tumors are discussed.

KW - Angiogenesis

KW - Cancer

KW - Gene therapy

KW - Hypoxia

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=77951496704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951496704&partnerID=8YFLogxK

U2 - 10.3109/08916930903510963

DO - 10.3109/08916930903510963

M3 - Article

C2 - 20166871

AN - SCOPUS:77951496704

VL - 43

SP - 244

EP - 247

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 3

ER -